

1

## SEQUENCE LISTING

&lt;110&gt; CTT Cancer Targeting Technologies Oy

&lt;120&gt; Method for designing peptides

&lt;130&gt; 41640

&lt;140&gt;

&lt;141&gt;

&lt;160&gt;

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
CTT2-peptide

&lt;400&gt; 1

Gly	Arg	Glu	Asn	Tyr	His	Gly	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu
1				5				10						15	

Cys

&lt;210&gt; 2

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Lys-substitution of the CTT2-peptide

&lt;400&gt; 2

Lys	Arg	Glu	Asn	Tyr	His	Gly	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu
1				5				10						15	

Cys

&lt;210&gt; 3

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

2

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:

CTT2-peptide with additional Lys

&lt;400&gt; 3

Gly	Arg	Glu	Asn	Tyr	His	Gly	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu
1					5				10					15	

Cys Lys

&lt;210&gt; 4

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:

CTT2-peptide with a tryptophan analogue at position 12

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; Xaa at position 12 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

&lt;400&gt; 4

Gly	Arg	Glu	Asn	Tyr	His	Gly	Cys	Thr	Thr	His	Xaa	Gly	Phe	Thr	Leu
1					5				10					15	

Cys